JP2017536354A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536354A5 JP2017536354A5 JP2017523975A JP2017523975A JP2017536354A5 JP 2017536354 A5 JP2017536354 A5 JP 2017536354A5 JP 2017523975 A JP2017523975 A JP 2017523975A JP 2017523975 A JP2017523975 A JP 2017523975A JP 2017536354 A5 JP2017536354 A5 JP 2017536354A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fragment
- item
- seq
- isolated antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims description 33
- 108010056852 Myostatin Proteins 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 29
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims description 25
- 239000012634 fragment Substances 0.000 claims description 21
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 16
- 208000021642 Muscular disease Diseases 0.000 claims description 13
- 201000009623 Myopathy Diseases 0.000 claims description 13
- 108091005804 Peptidases Proteins 0.000 claims description 5
- 239000004365 Protease Substances 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 239000012472 biological sample Substances 0.000 claims description 4
- 230000008105 immune reaction Effects 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 230000017854 proteolysis Effects 0.000 claims description 4
- 239000011541 reaction mixture Substances 0.000 claims description 4
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims description 3
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 claims description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 102000035195 Peptidases Human genes 0.000 claims description 2
- 230000009918 complex formation Effects 0.000 claims description 2
- 238000010494 dissociation reaction Methods 0.000 claims description 2
- 230000005593 dissociations Effects 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108010023082 activin A Proteins 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 239000000203 mixture Substances 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 108010059616 Activins Proteins 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 102100026818 Inhibin beta E chain Human genes 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 239000000488 activin Substances 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000002638 denervation Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000006437 Proprotein Convertases Human genes 0.000 description 1
- 108010044159 Proprotein Convertases Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000000891 luminescent agent Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 235000020938 metabolic status Nutrition 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462076230P | 2014-11-06 | 2014-11-06 | |
| US62/076,230 | 2014-11-06 | ||
| US201562100361P | 2015-01-06 | 2015-01-06 | |
| US62/100,361 | 2015-01-06 | ||
| US201562187348P | 2015-07-01 | 2015-07-01 | |
| US62/187,348 | 2015-07-01 | ||
| US201562219094P | 2015-09-15 | 2015-09-15 | |
| US62/219,094 | 2015-09-15 | ||
| PCT/US2015/059468 WO2016073853A1 (en) | 2014-11-06 | 2015-11-06 | Anti-pro/latent-myostatin antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020085618A Division JP2020127430A (ja) | 2014-11-06 | 2020-05-15 | 抗プロ／潜在型−ミオスタチン抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017536354A JP2017536354A (ja) | 2017-12-07 |
| JP2017536354A5 true JP2017536354A5 (enExample) | 2018-12-13 |
| JP6706617B2 JP6706617B2 (ja) | 2020-06-10 |
Family
ID=55909861
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523975A Active JP6706617B2 (ja) | 2014-11-06 | 2015-11-06 | 抗プロ／潜在型−ミオスタチン抗体およびその使用 |
| JP2020085618A Withdrawn JP2020127430A (ja) | 2014-11-06 | 2020-05-15 | 抗プロ／潜在型−ミオスタチン抗体およびその使用 |
| JP2022130847A Pending JP2022166238A (ja) | 2014-11-06 | 2022-08-19 | 抗プロ／潜在型－ミオスタチン抗体およびその使用 |
| JP2024077058A Pending JP2024109663A (ja) | 2014-11-06 | 2024-05-10 | 抗プロ／潜在型－ミオスタチン抗体およびその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020085618A Withdrawn JP2020127430A (ja) | 2014-11-06 | 2020-05-15 | 抗プロ／潜在型−ミオスタチン抗体およびその使用 |
| JP2022130847A Pending JP2022166238A (ja) | 2014-11-06 | 2022-08-19 | 抗プロ／潜在型－ミオスタチン抗体およびその使用 |
| JP2024077058A Pending JP2024109663A (ja) | 2014-11-06 | 2024-05-10 | 抗プロ／潜在型－ミオスタチン抗体およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US10307480B2 (enExample) |
| EP (1) | EP3215175A4 (enExample) |
| JP (4) | JP6706617B2 (enExample) |
| AU (3) | AU2015342936B2 (enExample) |
| CA (1) | CA3005158A1 (enExample) |
| HK (1) | HK1243940A1 (enExample) |
| WO (1) | WO2016073853A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2568436T3 (es) | 2006-03-31 | 2016-04-29 | Chugai Seiyaku Kabushiki Kaisha | Procedimiento para controlar la farmacocinética en sangre de anticuerpos |
| BRPI0817294A2 (pt) | 2007-09-26 | 2015-03-17 | Chugai Pharmaceutical Co Ltd | Método de modificação do ponto isoelétrico de anticorpo via substituição de aminoácido em cdr. |
| EP3056513A1 (en) | 2008-04-11 | 2016-08-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| KR102568454B1 (ko) | 2010-11-30 | 2023-08-18 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자 |
| EP2889376A4 (en) | 2012-08-24 | 2016-11-02 | Chugai Pharmaceutical Co Ltd | MOUSE FC RII SPECIFIC FC ANTIBODY |
| TW202237660A (zh) | 2012-08-24 | 2022-10-01 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
| WO2014163101A1 (ja) | 2013-04-02 | 2014-10-09 | 中外製薬株式会社 | Ｆｃ領域改変体 |
| PL2981822T3 (pl) * | 2013-05-06 | 2021-07-12 | Scholar Rock, Inc. | Kompozycje i sposoby modulacji czynnika wzrostu |
| US10307480B2 (en) | 2014-11-06 | 2019-06-04 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| EP4600372A3 (en) | 2014-12-19 | 2025-11-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| KR102605798B1 (ko) | 2015-02-05 | 2023-11-23 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용 |
| PT3653221T (pt) | 2015-02-19 | 2022-11-08 | Compugen Ltd | Anticorpos anti-pvrig e métodos de utilização |
| HRP20250666T1 (hr) | 2015-09-15 | 2025-08-01 | Scholar Rock, Inc. | Anti-pro/latentna miostatinska protutijela i njihove uporabe |
| KR101820637B1 (ko) * | 2015-12-18 | 2018-01-19 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE |
| CN109071645A (zh) | 2016-01-08 | 2018-12-21 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 |
| DK3368069T3 (da) * | 2016-06-13 | 2020-11-02 | Scholar Rock Inc | Anvendelse af myostatininhibitorer og kombinationsterapier |
| CN109311969B (zh) * | 2016-06-17 | 2022-09-27 | 中外制药株式会社 | 抗-肌肉生长抑制因子抗体及使用方法 |
| US11053308B2 (en) | 2016-08-05 | 2021-07-06 | Chugai Seiyaku Kabushiki Kaisha | Method for treating IL-8-related diseases |
| DK3565592T5 (da) * | 2017-01-06 | 2024-09-02 | Scholar Rock Inc | Behandling af stofskiftesygdomme ved inhibering af myostatinaktivering |
| PT3565592T (pt) | 2017-01-06 | 2023-05-31 | Scholar Rock Inc | Tratamento de doenças metabólicas através da inibição da ativação da miostatina |
| MA52165A (fr) | 2018-07-11 | 2021-06-02 | Scholar Rock Inc | Inhibiteurs sélectifs de l'isoforme tgfbeta1 et utilisation associée |
| CN112996535A (zh) | 2018-07-11 | 2021-06-18 | 供石公司 | 高亲和性、亚型选择性TGFβ1抑制剂及其用途 |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| JP2024524159A (ja) | 2021-06-23 | 2024-07-05 | スカラー ロック インコーポレイテッド | 代謝障害の治療における使用のためのｇｌｐ－１経路活性化剤と組み合わせたミオスタチン経路阻害剤 |
| WO2023079430A1 (en) * | 2021-11-02 | 2023-05-11 | Pfizer Inc. | Methods of treating mitochondrial myopathies using anti-gdf15 antibodies |
| CN114891101B (zh) * | 2021-12-02 | 2023-06-16 | 吉林省农业科学院 | 一种牛肌肉生长抑制素蛋白单克隆抗体及其应用 |
| TW202430247A (zh) | 2022-12-22 | 2024-08-01 | 美商供石公司 | 肌肉生長抑制素活化之選擇性及強效抑制劑 |
| EP4676954A1 (en) | 2023-03-07 | 2026-01-14 | Scholar Rock, Inc. | Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients |
| WO2025240343A1 (en) | 2024-05-13 | 2025-11-20 | Scholar Rock, Inc. | Tgf-beta inhibitors for treating cancer |
| WO2025245160A1 (en) | 2024-05-21 | 2025-11-27 | Scholar Rock, Inc. | Myostatin-selective inhibitors for treating metabolic disorders |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7566768B1 (en) | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| DE69432815T2 (de) | 1993-03-19 | 2003-12-11 | The Johns Hopkins University School Of Medicine, Baltimore | Wachstumsfaktor-8 |
| US20030167492A1 (en) | 1994-07-08 | 2003-09-04 | Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same |
| CA2194660C (en) | 1994-07-08 | 2009-09-29 | Se-Jin Lee | Growth differentiation factor-11 |
| US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| FR2804102B1 (fr) | 2000-01-26 | 2002-08-16 | Rhodia Terres Rares | Dispersion colloidale aqueuse d'un compose de cerium et d'au moins un autre element choisi parmi les terres rares, des metaux de transition, l'aluminium, le gallium et le zirconium, procede de preparation et utilisation |
| KR20020090211A (ko) | 2000-01-28 | 2002-11-30 | 노보 노르디스크 에이/에스 | 알키닐 치환된 프로피온산 유도체 및 당뇨병 및 비만에대한 그것의 사용 |
| PT2275449T (pt) * | 2000-06-16 | 2016-12-27 | Human Genome Sciences Inc | Anticorpos que se ligam imunoespecificamente a blys |
| AU2011244851A1 (en) * | 2000-07-27 | 2011-11-24 | The John Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| US7320789B2 (en) * | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| ES2288900T3 (es) | 2001-10-05 | 2008-02-01 | Affimed Therapeutics Ag | Anticuerpo de origen humano para inhibir la agregacion de trombocitos. |
| US8455627B2 (en) * | 2001-10-05 | 2013-06-04 | Affimed Therapeutics, Ag | Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa |
| CA2493067A1 (en) | 2002-07-19 | 2004-01-29 | Abbott Biotechnology Ltd. | Treatment of tnf.alpha. related disorders |
| EP2192129A1 (en) | 2002-09-16 | 2010-06-02 | Johns Hopkins University | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
| AR047392A1 (es) * | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| US7285269B2 (en) * | 2002-12-02 | 2007-10-23 | Amgen Fremont, Inc. | Antibodies directed to tumor necrosis factor |
| KR20160045936A (ko) | 2002-12-20 | 2016-04-27 | 암겐 인코포레이티드 | 미오스타틴을 저해하는 결합제 |
| UA93855C2 (ru) * | 2003-12-31 | 2011-03-25 | Шеринг-Плау Лтд. | Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе |
| JP2007526337A (ja) | 2004-03-02 | 2007-09-13 | アクセルロン ファーマ インコーポレーテッド | Ａｌｋ７およびミオスタチン阻害剤ならびにその使用 |
| MXPA06010929A (es) | 2004-03-23 | 2007-01-16 | Lilly Co Eli | Anticuerpos anti-miostatina. |
| JP5848861B2 (ja) | 2004-04-20 | 2016-01-27 | ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ | Ｃｄ２０に対するヒトモノクローナル抗体 |
| KR20070026650A (ko) | 2004-05-27 | 2007-03-08 | 악셀레론 파마 인코포레이티드 | 케르베루스/코코 유도체 및 그의 용도 |
| AU2005271523B2 (en) | 2004-08-03 | 2011-09-15 | Dyax Corp. | hk1-binding proteins |
| AU2006208286A1 (en) * | 2005-01-26 | 2006-08-03 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
| US20060216279A1 (en) | 2005-03-22 | 2006-09-28 | Glass David J | Myostatin inhibiting fusion polypeptides and therapeutic methods thereof |
| EA015534B1 (ru) | 2005-04-25 | 2011-08-30 | Пфайзер Инк. | Антитела к миостатину и способы их применения |
| HUE025240T2 (en) | 2005-08-19 | 2016-03-29 | Wyeth Llc | Anti-GDF-8 antagonist antibodies and their use in the treatment of ALS and other disorders associated with GDF-8 |
| US7635760B2 (en) | 2005-10-06 | 2009-12-22 | Eli Lilly And Company | Anti-myostatin antibodies |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| WO2007061995A2 (en) * | 2005-11-21 | 2007-05-31 | Novartis Ag | Biomarkers for statin-induced myopathy or rhabdomyolysis |
| US8097596B2 (en) | 2006-06-30 | 2012-01-17 | Lakewood-Amedex, Inc. | Compositions and methods for the treatment of muscle wasting |
| DK2054434T3 (en) * | 2006-08-03 | 2017-07-03 | Myostin Therapeutics Pty Ltd | Myostatin antagonists |
| KR101123531B1 (ko) | 2006-09-05 | 2012-04-20 | 일라이 릴리 앤드 캄파니 | 항-마이오스타틴 항체 |
| ES2569365T3 (es) | 2006-11-29 | 2016-05-10 | Nationwide Children's Hospital | Inhibición de miostatina para la potenciación de músculo y/o la mejora de la función muscular |
| JP5670179B2 (ja) | 2007-03-30 | 2015-02-18 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 負の光学的分散を有する複屈折層 |
| EP2162152A2 (en) * | 2007-06-01 | 2010-03-17 | Biogen Idec MA, Inc. | Cripto binding molecules |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| AU2009246687B2 (en) * | 2008-05-13 | 2012-08-09 | Irm Llc | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors |
| TW201029662A (en) * | 2008-12-19 | 2010-08-16 | Glaxo Group Ltd | Novel antigen binding proteins |
| WO2010099219A2 (en) | 2009-02-24 | 2010-09-02 | The Salk Institute For Biological Studies | Designer ligands of tgf-beta superfamily |
| US20120022057A1 (en) * | 2009-03-18 | 2012-01-26 | Schering Corporation | Bicyclic compounds as inhibitors of diacyglycerol acyltransferase |
| SG174273A1 (en) | 2009-04-27 | 2011-10-28 | Novartis Ag | Compositions and methods for increasing muscle growth |
| EP2440576A4 (en) | 2009-06-08 | 2013-11-20 | Acceleron Pharma Inc | PROCESS FOR INCREASING THE NUMBER OF THERMOUS ADIPOCYTES |
| US8945511B2 (en) | 2009-06-25 | 2015-02-03 | Paul Weinberger | Sensitive methods for detecting the presence of cancer associated with the over-expression of galectin-3 using biomarkers derived from galectin-3 |
| EP2483300A4 (en) | 2009-10-01 | 2013-02-27 | Covita Ltd | SYNTHETIC PEPTIDE ANTAGONISTS OF MYOSTATIN |
| EP3511342B1 (en) | 2010-03-10 | 2024-01-17 | Genmab A/S | Monoclonal antibodies against c-met |
| TWI667346B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| US8999343B2 (en) * | 2010-08-16 | 2015-04-07 | Amgen Inc. | Antibodies that bind myostatin, compositions and methods |
| WO2013071056A2 (en) | 2011-11-11 | 2013-05-16 | Duke University | Combination drug therapy for the treatment of solid tumors |
| HUE038570T2 (hu) * | 2011-11-14 | 2018-10-29 | Regeneron Pharma | Készítmények és eljárások izomtömeg és izomerõ növelésére GDF8 és/vagy aktivin A specifikus antagonizálásával |
| US20130178454A1 (en) | 2011-11-17 | 2013-07-11 | Shalender Bhasin | Combination of testosterone and ornithine decarboxylase (odc) inhibitors |
| WO2013148284A1 (en) | 2012-03-29 | 2013-10-03 | Genentech, Inc. | Antibodies that bind to a pcsk9 cleavage site and methods of use |
| WO2013165972A2 (en) | 2012-04-30 | 2013-11-07 | Cell Signaling Technology, Inc. | Anti-hepatitis b virus antibodies and use thereof |
| KR101704893B1 (ko) | 2012-06-15 | 2017-02-08 | 화이자 인코포레이티드 | Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도 |
| MX388059B (es) * | 2012-11-06 | 2025-03-19 | Scholar Rock Inc | Composiciones y metodos para modular la comunicacion celular. |
| PL2981822T3 (pl) | 2013-05-06 | 2021-07-12 | Scholar Rock, Inc. | Kompozycje i sposoby modulacji czynnika wzrostu |
| EP2853898B1 (en) * | 2013-09-27 | 2017-01-04 | Medizinische Hochschule Hannover | Analysis of myostatin in serum |
| CA2929574A1 (en) | 2013-11-11 | 2015-05-14 | Sirna Therapeutics, Inc. | Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moiety |
| WO2015195094A1 (en) | 2014-06-17 | 2015-12-23 | Ember Therapeutics, Inc. | Anti-activin and nati-myostatin antibodies and methods of using the same |
| WO2016073879A2 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Transforming growth factor-related antibodies and uses thereof |
| US10307480B2 (en) | 2014-11-06 | 2019-06-04 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| EP4600372A3 (en) * | 2014-12-19 | 2025-11-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| EA201792298A1 (ru) | 2015-04-15 | 2018-04-30 | Регенерон Фармасьютикалз, Инк. | Способы увеличения силы и функциональности с помощью ингибиторов gdf8 |
| HRP20250666T1 (hr) | 2015-09-15 | 2025-08-01 | Scholar Rock, Inc. | Anti-pro/latentna miostatinska protutijela i njihove uporabe |
| CN109071645A (zh) | 2016-01-08 | 2018-12-21 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 |
| DK3368069T3 (da) | 2016-06-13 | 2020-11-02 | Scholar Rock Inc | Anvendelse af myostatininhibitorer og kombinationsterapier |
| JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
| DK3565592T5 (da) | 2017-01-06 | 2024-09-02 | Scholar Rock Inc | Behandling af stofskiftesygdomme ved inhibering af myostatinaktivering |
-
2015
- 2015-11-06 US US15/524,651 patent/US10307480B2/en active Active
- 2015-11-06 WO PCT/US2015/059468 patent/WO2016073853A1/en not_active Ceased
- 2015-11-06 HK HK18103508.9A patent/HK1243940A1/zh unknown
- 2015-11-06 AU AU2015342936A patent/AU2015342936B2/en active Active
- 2015-11-06 EP EP15857125.7A patent/EP3215175A4/en active Pending
- 2015-11-06 JP JP2017523975A patent/JP6706617B2/ja active Active
- 2015-11-06 CA CA3005158A patent/CA3005158A1/en active Pending
-
2019
- 2019-04-04 US US16/374,854 patent/US11135291B2/en active Active
-
2020
- 2020-05-15 JP JP2020085618A patent/JP2020127430A/ja not_active Withdrawn
- 2020-12-22 AU AU2020294193A patent/AU2020294193B2/en active Active
-
2021
- 2021-09-03 US US17/446,897 patent/US11925683B2/en active Active
-
2022
- 2022-08-19 JP JP2022130847A patent/JP2022166238A/ja active Pending
-
2024
- 2024-02-02 US US18/431,294 patent/US20240374718A1/en active Pending
- 2024-05-10 JP JP2024077058A patent/JP2024109663A/ja active Pending
- 2024-05-14 AU AU2024203178A patent/AU2024203178A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536354A5 (enExample) | ||
| JP7785107B2 (ja) | 抗プロ／潜在型ミオスタチン抗体およびその使用 | |
| US11925683B2 (en) | Compositions for making and using anti-Myostatin antibodies | |
| CN107922503B (zh) | 一种pdl-1抗体、其药物组合物及其用途 | |
| CN114341186B (zh) | 双特异性抗LRRC15和CD3ε抗体 | |
| JP2019527194A5 (enExample) | ||
| AU2015228454A1 (en) | Anti-MCAM antibodies and associated methods of use | |
| EP4292611A1 (en) | Anti-cd112r antibody and use thereof | |
| WO2013183786A1 (ja) | トランスポーターに対する抗体およびその用途 | |
| RU2019134462A (ru) | Антитела, связывающиеся с steap-1 | |
| EP3845560A1 (en) | Antibody against il-1?, pharmaceutical composition and use thereof | |
| CA3208455A1 (en) | Novel anti-gremlin1 antibodies | |
| WO2021013142A1 (zh) | 抗4-1bb抗体、其抗原结合片段及双特异性抗体 | |
| WO2020169062A1 (zh) | 抗pd-l1抗体及其用途 | |
| KR20230034367A (ko) | 항-종양 괴사 인자 수용체 (tnfr2) 항체 및 그 용도 | |
| US20260035455A1 (en) | ANTI-IL-1ß ANTIBODY AND PHARMACEUTICAL COMPOSITION THEREOF AND USE OF SAME | |
| CN108064250A (zh) | 抗-cd20-/抗-baff双特异性抗体 | |
| AU2023375570A1 (en) | Cytotoxic bispecific antibodies binding to dr5 and muc16 and uses thereof | |
| TW202523697A (zh) | 抗ｔｓｌｐ抗體構築體及其用途 | |
| TW202537974A (zh) | Ｔｒｇｖ９結合蛋白及其醫藥用途 | |
| TW202506733A (zh) | 淋巴毒素β受體促效劑結合蛋白 | |
| CN121057749A (zh) | 抗cd3多特异性抗体和使用方法 | |
| HK40093421A (zh) | 新颖的抗gremlin1抗体 | |
| HK40089230A (zh) | 药物组合物及用途 | |
| TW202214303A (zh) | 用於癌症治療之結合分子 |